Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 393

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 393
---
 2 genetic tests priced at approximately U.S.$40), mid -range(e.g., Gut Microbiome Studies or Hereditary Cancer Panels, ranging approximately from U.S.$65 to U.S.$165), and advanced panels (e.g., Clinical Exome Trio analyses or Myeloid Panels, with prices ranging approximately from U.S.$210 to U.S.$355). For more information, see “ Risk Factors — Risks Related to Our Business and Strategy — We depend on CIBIC, one of our indirect shareholders, for a substantial part of our revenues, and if the Commercialization Agreement is terminated, our business and results of operations would be materially adversely affected” and “ Certain Company Relationships and Related Party Transactions.” Meyer On January 25, 2021, we entered into a distribution agreement with Meyer Lab S.A. (“Meyer”) in Paraguay pursuant to which we provide clinical genetic diagnostic tests from our Heritas Diagnostics division to Meyer. We process and perform the sequencing of samples provided by Meyer and we deliver the results to Meyer. Our services include receiving and evaluating the quality of genetic material (DNA and RNA) from submitted samples, performing sequencing using Illumina’s next -generationsequencing instruments, conducting bioinformatics analysis, interpreting genetic variants associated with health conditions, and generating diagnostic reports. Additionally, we provide pre- and post -testgenetic counseling as part of our services under the distribution agreement. Invoicing occurs monthly on the last day of each month and includes a detailed breakdown of the services provided. Payments are due within 15 days of the invoice date. Pricing for services is governed by the terms outlined in the agreement’s annex, and Heritas, or one of its affiliates, may issue invoices with prior notice to Meyer. These invoicing procedures do not alter the obligations of Meyer under the agreement. Under our agreement with Meyer, genomic diagnostic services offered through the Heritas Diagnostics division encompass various applications, including reproductive health, rare diseases, hereditary cancer, and human microbiome analysis. These services include sample quality control, sequencing performed on Illumina platforms, bioinformatic data analysis, interpretation of genetic variants related to health conditions, and the generation of genomic diagnostic reports. The percentage of revenue attributable to the distribution agreement with Meyer is approximately 1.2% of our total revenues for the period reported in this prospectus. On March 11, 2024, we entered into a services agreement with Meyer in Paraguay, as amended on November1, 2024, pursuant to which we process and